4D-150 IVT (3E10 vg/eye)

Phase 3

4D Molecular Therapeutics, Inc. (FDMT)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

FDMTPhase 3$481M

4D-150 IVT (3E10 vg/eye) Phase 3 Est. Readout

4D-150 IVT (3E10 vg/eye)• Neovascular Age-Related Macular Degeneration (nAMD)480

Jun 2027~Confirmed

CT.gov

00%

Competitive Landscape

2 competitors in Neovascular Age-Related Macular Degeneration (nAMD)

RHHBYVabysmo

RHHBYranibizumab injection

Approved

View Full Landscape

Drug Information

Target Indication

Neovascular Age-Related Macular Degeneration (nAMD)

Clinical Trial

NCT07064759

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

FDMT

4D Molecular Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

11C-choline InjectionPhase 3

Metastatic Prostate Cancer

4D-310Phase 2

Fabry Disease

4D-710Phase 2

Cystic Fibrosis Lung

4D-125 IVT InjectionPhase 2

X-Linked Retinitis Pigmentosa

4D-150 IVTPhase 2

Diabetic Macular Edema

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts